Use APKPure App
Get SFA Lite old version APK for Android
Cuztomise enables Pharmaceutical firms to efficiently manage Sales Professionals
Cuztomise Pharma is a highly specific software solution designed to suit the unique requirements of a Pharmaceuticals company with respect to managing its field force of Medical Representatives. Supervisors or team leaders can get full information on the visit time to the medical facility, tasks carried out at the time of the operation, in order to monitor the route and duties of their employees.
# Plan monthly and daily activities follow-ups
# Know location of your medical representatives in real time and optimize their deployment
# Easily find out deviations, missed doctor calls and verify if your MRs visit his territory doctors
# Easily get quick feedbacks from MRs about doctor visits and products
# Easily profile, target and measure performance of Medical Representative
# Allows mapping of doctors with products for focused marketing
# Enabled for both Online and Offline usage
# Saves time by automatically generating daily activity reports and not filling them manually.
# Updates the complete visit/call details and records attendance through mobile
Attrition Proof
With Cuztomise, your operations become attrition proof. Data mobility makes sure that expansion/realignment of medical representatives are very simple and takes near zero efforts.
Doctor Database
Cuztomise makes sure that a comprehensive database of doctors is build up over a time which helps you effectively plan future schedules/targets. This data can be shared with MR’s to improve conversion rates.
Product Feedback
Cuztomise app allows dynamic product/visits feedbacks to a central admin. This data is then analysed in a visually informative way which essentially means a better product sales roadmap
Last updated on Dec 1, 2024
Minor bug fixes and improvements. Install or update to the newest version to check it out!
Uploaded by
Alex Cacconie
Requires Android
Android 4.4+
Category
Report
SFA Lite
20.3 by Cuztomise
Dec 1, 2024